Celldex Therapeutics, Inc. (CLDX)
Stock Price:
$22.50 USD
-0.25 (-1.10%)
Updated November 30, 4:00 PM EST - Market closed
Key Info
| Market Cap |
890.26M |
| Revenue (ttm) |
4.52M |
| Net Income (ttm) |
-48.33M |
| Shares Out |
39.57M |
| EPS (ttm) |
-2.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$22.50 |
| Previous Close |
$22.75 |
| Change ($) |
-0.25 |
| Change (%) |
-1.10% |
| Day's Open |
22.92 |
| Day's Range |
21.74 - 22.97 |
| Day's Volume |
1,008,255 |
| 52-Week Range |
1.55 - 22.97 |
More Stats
| Market Cap |
890.26M |
| Enterprise Value |
694.47M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.57M |
| Float |
n/a |
| EPS (basic) |
-2.18 |
| EPS (diluted) |
-2.03 |
| FCF / Share |
-1.21 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.82M |
| Short Ratio |
6.42 |
| Short % of Float |
n/a |
| Beta |
2.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
197.00 |
| PB Ratio |
3.74 |
| Revenue |
4.52M |
| Operating Income |
-55.48M |
| Net Income |
-48.33M |
| Free Cash Flow |
-47.60M |
| Net Cash |
195.79M |
| Net Cash / Share |
4.95 |
| Gross Margin |
-865.02% |
| Operating Margin |
-1,227.73% |
| Profit Margin |
-1,069.40% |
| FCF Margin |
-1,053.40% |
| ROA |
-16.76% |
| ROE |
-29.17% |
| ROIC |
-47.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$26.33*
(17.02% upside)
Low
22.0
Current: $22.50
High
32.0
Target: 26.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 3.57 | 9.54 | 12.74 | 6.79 | 5.48 | 3.59 | 4.11 | 11.20 | 9.27 | 46.79 |
| Revenue Growth | -62.54% | -25.15% | 87.78% | 23.83% | 52.82% | -12.77% | -63.3% | 20.91% | -80.2% | - |
| Gross Profit | 3.57 | 9.54 | 12.74 | 6.79 | 5.48 | 3.59 | 1.78 | 0.43 | 0.15 | 34.72 |
| Operating Income | -56.33 | -186 | -122 | -133 | -130 | -122 | -81.44 | -58.08 | -43.40 | -6.46 |
| Net Income | -50.88 | -151 | -93.03 | -129 | -127 | -118 | -81.55 | -59.12 | -44.80 | -2.53 |
| Shares Outstanding | 14.51 | 10.44 | 8.57 | 6.77 | 6.47 | 5.96 | 5.32 | 3.85 | 2.63 | 2.12 |
| Earnings Per Share | -3.51 | -14.48 | -10.86 | -18.99 | -19.65 | -19.80 | -15.30 | -15.30 | -16.95 | -1.20 |
| Operating Cash Flow | -46.42 | -75.24 | -99.93 | -113 | -98.89 | -102 | -67.67 | -49.78 | -35.66 | -30.37 |
| Capital Expenditures | -0.73 | -0.81 | -1.79 | -2.75 | -4.88 | -1.93 | -4.22 | -0.30 | -0.51 | -2.10 |
| Free Cash Flow | -47.15 | -76.05 | -102 | -116 | -104 | -103 | -71.89 | -50.09 | -36.17 | -32.47 |
| Cash & Equivalents | 64.38 | 94.02 | 139 | 190 | 290 | 201 | 303 | 83.96 | 53.31 | 61.10 |
| Total Debt | 3.66 | - | - | - | - | - | - | 11.34 | 15.14 | 22.41 |
| Net Cash / Debt | 60.73 | 94.02 | 139 | 190 | 290 | 201 | 303 | 72.62 | 38.17 | 38.69 |
| Assets | 123 | 156 | 316 | 383 | 338 | 248 | 347 | 126 | 97.99 | 110 |
| Liabilities | 28.91 | 31.75 | 79.26 | 118 | 47.48 | 36.35 | 27.30 | 29.77 | 29.27 | 34.69 |
| Book Value | 94.03 | 124 | 236 | 265 | 290 | 212 | 320 | 95.77 | 68.72 | 75.26 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Celldex Therapeutics, Inc. |
| Country |
United States |
| Employees |
127 |
| CEO |
Anthony S. Marucci |
Stock Information
| Ticker Symbol |
CLDX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLDX |
| IPO Date |
March 10, 2008 |
Description
Celldex Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.